Clinical Trial Update: CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update involving CAR-T therapy targeting CD19 for acute myeloid leukemia across Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CAR-T CD19 for Acute Myeloid Leukemia with t(8;21) and CD19 expression

Snippet

Sponsor: Sheba Medical Center | Conditions: Acute Myeloid Leukemia | Phase 2, Phase 3 | Status: UNKNOWN